Molecular Advances in Preeclampsia and HELLP Syndrome
Preeclampsia (PE) constitutes one of the principal reasons for maternal and perinatal morbidity and mortality worldwide. The circumstance typically implicates formerly healthful normotensive women, after 20 weeks of gestation, typically withinside the third trimester, without regarded threat element...
Main Authors: | Angeliki Gardikioti, Theodora-Maria Venou, Eleni Gavriilaki, Evangelia Vetsiou, Ioulia Mavrikou, Konstantinos Dinas, Angelos Daniilidis, Efthymia Vlachaki |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/7/3851 |
Similar Items
-
Real-world data of thrombotic microangiopathy management: The key role of ADAMTS13 activity and complement testing
by: Eleni Gavriilaki, et al.
Published: (2021-05-01) -
Dysregulation of complement system in HELLP syndrome
by: Shi Chen, et al.
Published: (2021-10-01) -
Circulating ADAMTS-12 levels in early- and late-onset severe preeclampsia
by: Ayse Kirbas, et al.
Published: (2016-09-01) -
ADAMTS 1, 4, 12, and 13 levels in maternal blood, cord blood, and placenta in preeclampsia
by: Müberra Namlı Kalem, et al.
Published: (2018-01-01) -
ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura
by: Quintijn Bonnez, et al.
Published: (2023-09-01)